Baseline characteristics of LyMa-101 and LyMa maintenance populations before and after PSM
| Population . | Before matching (PS set) . | After PSM (matching set) . | Fisher test after PSM, P value . | ||
|---|---|---|---|---|---|
| Number . | LyMa, n = 78 . | LyMa-101, n = 59 . | R group, n = 43 . | O group, n = 43 . | |
| Sex | |||||
| Male | 62 (79.5%) | 41 (69.5%) | 33 (76.7%) | 36 (83.7%) | .59 |
| Female | 16 (20.5%) | 18 (30.5%) | 10 (23.3%) | 7 (16.3%) | |
| MIPI risk group | |||||
| Low | 43 (55.1%) | 37 (62.7%) | 26 (60.5%) | 28 (65.1%) | .74 |
| Intermediate | 23 (29.5%) | 14 (23.7%) | 9 (20.9%) | 10 (23.3%) | |
| High | 12 (15.4%) | 8 (13.6%) | 8 (18.6%) | 5 (11.6%) | |
| Ann Arbor stage | |||||
| II | 3 (3.8%) | 0 (0%) | — | — | 1 |
| III | 7 (9%) | 4 (6.8%) | 4 (9.3%) | 4 (9.3%) | |
| IV | 68 (87.2%) | 55 (93.2%) | 39 (90.7%) | 39 (90.7%) | |
| B symptoms | |||||
| No | 51 (65.4%) | 46 (78%) | 31 (72.1%) | 33 (76.7%) | .8 |
| Yes | 27 (34.6%) | 13 (22%) | 12 (27.9%) | 10 (23.3%) | |
| Blastoid variant | |||||
| No | 72 (92.3%) | 48 (81.4%) | 35 (88.4%) | 38 (88.4%) | 1 |
| Yes | 6 (7.7%) | 11 (18.6%) | 5 (11.6%) | 5 (11.6%) | |
| EOI | |||||
| MRD neg | 47 (60.3%) | 48 (81.4%) | 34 (79.1%) | 33 (76.7%) | 1 |
| PNQ | 22 (28.2%) | 9 (15.3%) | 7 (16.3%) | 8 (18.6%) | |
| Positive | 9 (11.5%) | 2 (3.4%) | 2 (4.7%) | 2 (4.7%) | |
| Population . | Before matching (PS set) . | After PSM (matching set) . | Fisher test after PSM, P value . | ||
|---|---|---|---|---|---|
| Number . | LyMa, n = 78 . | LyMa-101, n = 59 . | R group, n = 43 . | O group, n = 43 . | |
| Sex | |||||
| Male | 62 (79.5%) | 41 (69.5%) | 33 (76.7%) | 36 (83.7%) | .59 |
| Female | 16 (20.5%) | 18 (30.5%) | 10 (23.3%) | 7 (16.3%) | |
| MIPI risk group | |||||
| Low | 43 (55.1%) | 37 (62.7%) | 26 (60.5%) | 28 (65.1%) | .74 |
| Intermediate | 23 (29.5%) | 14 (23.7%) | 9 (20.9%) | 10 (23.3%) | |
| High | 12 (15.4%) | 8 (13.6%) | 8 (18.6%) | 5 (11.6%) | |
| Ann Arbor stage | |||||
| II | 3 (3.8%) | 0 (0%) | — | — | 1 |
| III | 7 (9%) | 4 (6.8%) | 4 (9.3%) | 4 (9.3%) | |
| IV | 68 (87.2%) | 55 (93.2%) | 39 (90.7%) | 39 (90.7%) | |
| B symptoms | |||||
| No | 51 (65.4%) | 46 (78%) | 31 (72.1%) | 33 (76.7%) | .8 |
| Yes | 27 (34.6%) | 13 (22%) | 12 (27.9%) | 10 (23.3%) | |
| Blastoid variant | |||||
| No | 72 (92.3%) | 48 (81.4%) | 35 (88.4%) | 38 (88.4%) | 1 |
| Yes | 6 (7.7%) | 11 (18.6%) | 5 (11.6%) | 5 (11.6%) | |
| EOI | |||||
| MRD neg | 47 (60.3%) | 48 (81.4%) | 34 (79.1%) | 33 (76.7%) | 1 |
| PNQ | 22 (28.2%) | 9 (15.3%) | 7 (16.3%) | 8 (18.6%) | |
| Positive | 9 (11.5%) | 2 (3.4%) | 2 (4.7%) | 2 (4.7%) | |
In this analysis, 78 and 59 patients in the R and O groups, respectively, were matched based on baseline characteristics and EOI MRD negativity, resulting in 2 groups of 43 each.
Fisher test was performed between the matched populations.
MRD neg, measurable residual disease negative.